Effects of Sage on Memory and Mental Performance in Alzheimer's Disease Patients
The purpose of this study is to determine the effectiveness of the herb sage in improving the mental function of individuals with Alzheimer's disease.
Study hypothesis: The administration of sage will improve cognitive function in patients with mild Alzheimer's disease.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||Effects of a Cognitive Enhancer on Memory and Cognitive Performance|
- Cognitive function [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
- Stress [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
- cognitive electrophysiology [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
|Study Start Date:||July 2005|
|Study Completion Date:||October 2014|
|Primary Completion Date:||December 2012 (Final data collection date for primary outcome measure)|
Sage capsules taken by mouth
Drug: Salvia officinalis (sage)
Other Name: sage
No Intervention: 2
No intervention, no-pill as control
The herb sage has been shown to enhance memory and mental function in healthy, young adults. However, studies assessing the herb's effectiveness in older adults with symptoms of Alzheimer's disease are limited. This study will determine the effect of sage extract on the cognitive function of patients with mild Alzheimer's disease.
This study will last 6 weeks and will comprise 4 study visits, approximately 10 days apart. Participants will be randomly assigned to receive either sage pills or no treatment during each 10-day period. The treatment assignments will be switched in 10-day intervals, so that during the course of the study, each participant will undergo two periods of sage treatment and two periods without treatment. At each study visit, participants will undergo cognitive testing, including tests to determine attention, memory, and visual cognition. Participants will also undergo an electroencephalogram (EEG) and an electrocardiogram (ECG) at each visit.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00110552
|United States, Oregon|
|Oregon Health and Science University|
|Portland, Oregon, United States, 97239|
|Principal Investigator:||Barry Oken, MD||Oregon Health and Science University|